Collectively, these data indicated that targeting PFKFB3-positive β-cells with “loser” signature by PFKFB3 inhibition leads to diminishment of dysfunctional “loser” β-cells, restoring glucose tolerance in the human-like model of T2D. The gene discussed is PFKFB3; the disease is type 2 diabetes mellitus.